arXiv:2607.03787v1 Announce Type: new Abstract: Accurately modeling biomolecular interactions is a central bottleneck in biology and therapeutic discovery. Here, we introduce Open Drug Discovery Engine (OpenDDE), an open-source, all-atom biomolecular foundation model that uses co-folding as the entry point to a scalable AI-driven drug discovery engine. Rather than treating structure prediction as an isolated endpoint, OpenDDE is designed as a shared structural reasoning layer for modeling sequence-structure-function relationships across biomolecular complexes, enabling complex structure predic
The release of OpenDDE, an open-source, all-atom biomolecular foundation model, signals a significant advancement in AI for drug discovery, making sophisticated tools more widely accessible.
This development can accelerate the pace of therapeutic discovery by democratizing access to advanced biomolecular modeling, potentially leading to faster and more efficient drug development cycles.
Drug discovery shifts from a bottlenecked process heavily reliant on proprietary systems to one potentially driven by collaborative, open-source AI, enabling a broader range of researchers to contribute.
- · Biotech startups
- · Academic research institutions
- · Pharmaceutical companies
- · AI developers in biomedicine
- · Proprietary drug discovery software vendors
- · R&D departments still relying on traditional methods
Open-source platforms for complex biomolecular modeling become more prevalent, fostering innovation.
The cost and time required for early-stage drug target identification and validation decrease significantly.
A new wave of AI-driven therapeutic discoveries emerges, addressing previously intractable diseases at an accelerated pace.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.AI